A once-daily pill version of the blockbuster therapy could reshape the obesity market – and investors are already asking how close Lilly is to a stock split.
U.S. stocks rose broadly on Wednesday, but Eli Lilly (LLY) investors had an especially sunny day. The FDA approved Foundayo, the company’s oral weight-loss pill, sending shares up nearly 4% to just below the $1,000 handle – far outpacing the S&P 500’s 0.7% gain.
Foundayo’s approval is a milestone because it shifts from injection to a once-daily pill. Lilly already dominates with Zepbound (weekly injection), but the oral option offers convenience and a lower price point: $149 per month for the lowest dose, starting April 6 via Lilly’s online platform LillyDirect.
“This is obesity care designed for the real world,” said CEO David Ricks.
Lilly now goes head-to-head with Novo Nordisk’s oral Wegovy. Foundayo’s molecule is more stable (allowing anytime dosing), though Wegovy showed higher weight-loss percentages in clinical trials. Lilly’s real edge? Over $55 billion committed to manufacturing expansion since 2020 – far more than Novo’s capacity. Wall Street expects Foundayo to capture significant market share quickly.
Currently, GLP-1 penetration among eligible U.S. obesity patients remains in the mid-single digits – a striking statistic that underscores the growth ahead. Lilly’s existing injectables are booming:
Beyond Foundayo, Lilly is also advancing another oral GLP-1 candidate, orforglipron.
With shares hovering just below $1,000, talk of a stock split is heating up. A split would improve liquidity and lower the barrier for retail investors – and it’s often seen as a signal of management’s confidence in long-term growth.
That confidence is backed by numbers:
Management notes that pricing pressure could drag revenue growth by a low-to-mid-teens percentage, but volume growth is expected to more than offset it – highlighting that demand for Lilly’s obesity drugs is both broad-based and durable.
The oral pill approval is more than a product milestone – it could reshape the entire obesity treatment market. With the stock approaching $1,000, a split seems a matter of when, not if. For investors, Lilly is building a long-term story fueled by oral formulations, massive manufacturing capacity, and a deep pipeline (36 active Phase 3 programs). The real question isn’t whether Lilly will split – it’s how high the next approval can take this stock.
